Skip to main content
JAGX
NASDAQ Life Sciences

300万美元债务减少，到期日延长提升Jaguar Health的资产负债表

feedReported by Acceswire
Sentiment info
Positive
Importance info
9
Price
$0.566
Mkt Cap
$2.206M
52W Low
$0.56
52W High
$15.48
Market data snapshot near publication time

summarizeSummary

Jaguar Health宣布通过重组和减少专利权使用费和债务义务，约减少300万美元，代表着10%的减少，从而显著加强了其资产负债表。该公司还将700万美元的有担保循环信用线的到期日延长了三年，并消除了48,212份认购权。这种积极的财务发展为该公司提供了至关重要的缓冲空间，尤其是在最近收到纳斯达克退市通知（由于未能满足最低报价要求）和发行高稀释性优先股股息之后。300万美元的义务减少极为重要，超过了公司当前的市场资本化。管理层表示计划追求进一步的债务重组机会，并专注于其crofelemer开发计划，这可能会吸引非稀释性资金。

在该公告发布时，JAGX的交易价格为$0.57，交易所为NASDAQ，所属行业为Life Sciences，市值约为$220.6万。 52周交易区间为$0.56至$15.48。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Acceswire。

show_chartPrice Chart

Share this article

Copied!

feed JAGX - Latest Insights

JAGX
Apr 27, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Jaguar Health Announces 1-for-35 Reverse Stock Split to Meet Nasdaq Listing Requirements
Sentiment: Negative
View Wiseek Article
JAGX
Apr 27, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
1-for-35 Reverse Stock Split Set for Jaguar Health as Nasdaq Grants Delisting Extension
Sentiment: Neutral
View Wiseek Article
JAGX
Apr 21, 2026, 8:22 AM EDT
Filing Type: PRE 14A
Importance Score:
10
Jaguar Health Seeks Shareholder Approval for Highly Dilutive $42.4M Financing to Address Capital Needs
Sentiment: Negative
View Wiseek Article
JAGX
Apr 21, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Stockholders Approve Massive Share Increase, Two Reverse Splits, and $10.8M Debt Conversion
Sentiment: Negative
View Wiseek Article
JAGX
Apr 13, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Jaguar Health to Leverage AI, Pursue FDA Breakthrough Status for Crofelemer in Rare Disease
Sentiment: Positive
View Wiseek Article
JAGX
Apr 09, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Jaguar Health Believes It Has Regained Nasdaq Stockholders' Equity Compliance, Averting Delisting Threat
Sentiment: Positive
View Wiseek Article
JAGX
Apr 08, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Jaguar Health Completes Pivotal Trial for Canine Diarrhea Drug Crofelemer, Eyes Full FDA Approval
Sentiment: Positive
View Wiseek Article
JAGX
Apr 07, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Jaguar Health Reports Deepening Losses and Nasdaq Delisting Threat Amidst 2025 Financials
Sentiment: Negative
View Wiseek Article
JAGX
Apr 07, 2026, 6:10 AM EDT
Filing Type: 10-K
Importance Score:
9
Jaguar Health Faces Imminent Nasdaq Delisting, Warns of Going Concern Amidst Massive Potential Dilution
Sentiment: Negative
View Wiseek Article
JAGX
Mar 24, 2026, 5:06 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Jaguar Health Seeks Shareholder Approval for Massive Dilution, Two Extreme Reverse Stock Splits
Sentiment: Negative
View Wiseek Article